$14.23 -0.91 (%) Celldex Therapeutics Inc - NASDAQ

Sep. 15, 2014 | 04:00 PM

Partner Headlines

  1. 5 Companies Developing New Cancer Drugs

    Benzinga | Aug. 19, 2014 | 13:20PM EST
  2. 5-Star Biotech Stock Watch: Celldex Therapeutics

    Benzinga | Jun. 25, 2014 | 15:30PM EST
  3. Top Healthcare Movers For June 9, 2014

    Benzinga | Jun. 9, 2014 | 14:27PM EST
  4. Mid-Afternoon Market Update: Markets Head Downward As Commodities Continue To Show Strength

    Benzinga | May. 14, 2014 | 15:49PM EST
  5. Celldex's Phase 1 Study of CDX-1401 Published in Science Translational Medicine

    Benzinga | Apr. 16, 2014 | 14:02PM EST
  6. Mid-Afternoon Market Update: Markets Recover Slightly As Healthcare Stocks Continue to Show Weakness

    Benzinga | Mar. 24, 2014 | 15:33PM EST
  7. Mid-Day Market Update: NASDAQ Tumbles 1.65%; Nu Skin Shares Surge After AIC China Review Update

    Benzinga | Mar. 24, 2014 | 12:48PM EST
  8. Mid-Morning Market Update: Markets Mostly Lower; ReneSola Swings To Q4 Profit

    Benzinga | Mar. 24, 2014 | 10:35AM EST
  9. Morning Market Losers

    Benzinga | Mar. 3, 2014 | 10:23AM EST
  10. Earnings Scheduled For March 3, 2014

    Benzinga | Mar. 3, 2014 | 04:42AM EST
  11. Trade of the Day: Long CLDX

    Benzinga | Jan. 2, 2014 | 15:31PM EST
  12. Celldex Therapeutics Prices 7M Share Offering at $24.50/Share

    Benzinga | Dec. 4, 2013 | 21:00PM EST
  13. Celldex Therapeutics Announces 6.5M Share Offering

    Benzinga | Dec. 3, 2013 | 16:05PM EST
  14. Celldex Therapeutics Initiates Accelerated Approval Study of Glembatumumab Vedotin in Patients with Triple Negative Breast Cancer

    Benzinga | Dec. 2, 2013 | 07:07AM EST
  15. Mid-Afternoon Market Update: Markets Turn Back as Momentum Stocks Drop

    Benzinga | Nov. 25, 2013 | 15:48PM EST
  16. Mid-Day Market Update: SeaDrill Drops On Downbeat Earnings; Giant Interactive Shares Spike Higher

    Benzinga | Nov. 25, 2013 | 13:04PM EST
  17. Benzinga's Top #PreMarket Losers

    Benzinga | Nov. 25, 2013 | 08:20AM EST
  18. Celldex Therapeutics Presents Positive Phase 2 Rindopepimut Data in Patients with Recurrent Glioblastoma

    Benzinga | Nov. 24, 2013 | 15:37PM EST
  19. Downside Protection For Regeneron Pharmaceuticals

    Benzinga | Nov. 15, 2013 | 13:34PM EST
  20. Celldex Announces Publication of Preliminary Data from Phase 2 ReACT Study of Rindopepimut Vaccine Plus Bevacizumab

    Benzinga | Nov. 11, 2013 | 07:06AM EST
  21. Mid-Afternoon Market Update: Twitter IPO a Wild Success as Markets Slide

    Benzinga | Nov. 7, 2013 | 15:20PM EST
  22. Celldex Therapeutics' CDX-1127 Well Tolerated and Demonstrates Anti-Tumor Activity in Phase 1 Dose-Escalation Study

    Benzinga | Nov. 7, 2013 | 08:04AM EST
  23. Celldex to Present Dat at SITC, SNO Annual Meetings

    Benzinga | Oct. 21, 2013 | 12:31PM EST
  24. Pharmaceutical Industry Expected To Collect Billions From Obamacare

    Benzinga | Oct. 2, 2013 | 12:51PM EST
  25. Market Wrap For Monday, September 23: Markets Unmoved Despite Kenyan Terror

    Benzinga | Sep. 23, 2013 | 16:19PM EST
  26. Mid-Afternoon Market Update: Celldex Therapeutics Rallies as Pandora Drops

    Benzinga | Sep. 23, 2013 | 15:39PM EST
  27. These ETFs House The Next Biotech Takeover Targets

    Benzinga | Aug. 26, 2013 | 07:44AM EST
  28. Mid-Day Market Update: Sysco Drops On Q4 Results, McEwen Mining Shares Rise

    Benzinga | Aug. 12, 2013 | 12:32PM EST
  29. Mid-Morning Market Update: US Markets Mixed, BlackBerry To Explore Strategic Alternatives

    Benzinga | Aug. 12, 2013 | 10:25AM EST
  30. Celldex Announces Expansion of Phase 2 ReACT Study in Recurrent Glioblastoma

    Benzinga | Aug. 12, 2013 | 08:03AM EST
  31. Celldex Reports Phase 1 Study Results of CDX-301, Says Data Support Starting Pilot Study

    Benzinga | Feb. 14, 2013 | 01:11AM EST
  32. Celldex Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Added Shares

    Benzinga | Feb. 8, 2013 | 01:06AM EST
  33. Celldex's CDX-301 Safely Mobilizes Hematopoietic Cells in Phase 1 Study

    Benzinga | Dec. 11, 2012 | 01:15AM EST
  34. UPDATE: Oppenheimer Raises PT to $10 on Celldex Therapeutics on Improved Approval Outlook

    Benzinga | Dec. 10, 2012 | 06:28AM EST
  35. UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Celldex Therapeutics

    Benzinga | Dec. 10, 2012 | 05:05AM EST
  36. Morning Market Movers

    Benzinga | Dec. 10, 2012 | 02:54AM EST
  37. Benzinga's Top Pre-Market Gainers

    Benzinga | Dec. 10, 2012 | 01:11AM EST
  38. Celldex Posts Positive 3-Year Survival Data from Phase 2 Rindopepimut Program

    Benzinga | Nov. 15, 2012 | 10:10AM EST
  39. CELLDEX THERAPEUTICS, INC Reports Operating Results (10-Q)

    GuruFocus | Nov. 2, 2012 | 05:03AM EST
  40. UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Celldex Therapeutics

    Benzinga | Nov. 2, 2012 | 03:27AM EST
  41. UPDATE: Cantor Fitzgerald Reiterates Buy Rating, Raises PT on Celldex Therapeutics

    Benzinga | Sep. 14, 2012 | 04:55AM EST
  42. Earnings Scheduled For August 10, 2012

    Benzinga | Aug. 9, 2012 | 21:18PM EST
  43. Social Media Outlook for Thursday May 24 (HNZ, PAY, RIMM, NTAP)

    Benzinga | May. 24, 2012 | 06:20AM EST
  44. From Yesterday, Celldex's CDX-011 Demonstrates High Response Rates in Patients with Metastatic Breast Cancer Expressing Elevated Levels of GPNMB and in Triple Negative Disease

    Benzinga | May. 24, 2012 | 01:18AM EST
  45. Celldex Therapeutics Added to Nasdaq Biotechnology Index

    Benzinga | May. 15, 2012 | 03:30AM EST
  46. Notable Put Options Activity in Celldex Therapeutics

    Benzinga | Mar. 6, 2012 | 06:28AM EST
  47. 5 Resilient Biotech Stocks to Buy for 2012

    GuruFocus | Feb. 28, 2012 | 10:23AM EST
  48. Notable Put Options Activity in Celldex Therapeutics

    Benzinga | Feb. 27, 2012 | 06:04AM EST
  49. Benzinga's Microcap Movers for Tuesday January 17, 2012

    Benzinga | Jan. 17, 2012 | 13:19PM EST
Trading Center